Zenflow Secures $52 Million in Series D Funding Led by Cook Medical

Zenflow Raises $52 Million in Series D Funding

Zenflow, based in South San Francisco, California, has successfully raised $52 million in a Series D funding round. The round was spearheaded by Cook Medical, a prominent player in the medical device industry. Other participants included ClavystBio, Invus Opportunities, F-Prime, and Medtech Venture Partners.

Company Overview

Zenflow is known for its Zenflow Spring® System, a product designed to provide long-lasting relief for individuals suffering from benign prostatic hyperplasia (BPH) without causing side effects or requiring surgical intervention. The system is FDA-approved and boasts a 62% improvement in symptoms within 12 months, with no need for reintervention.

Strategic Use of Funds

The newly acquired funds will be directed towards the commercialization of the Zenflow Spring® System, following its premarket approval (PMA) from the U.S. Food and Drug Administration in December 2025. This system offers a new treatment category for BPH, termed first-line interventional therapy (FIT), providing a device-based alternative to drug therapy.

Exclusive Partnership

In addition to the funding, Zenflow has entered into an exclusive U.S. distribution agreement with Cook Medical. This partnership is expected to enhance the reach and availability of the Zenflow Spring® System across the United States, offering physicians a reliable treatment option for their patients with BPH.

Shreya Mehta, President and CEO of Zenflow, commented on the development, emphasizing the significant impact this partnership and funding will have on the company's growth and the availability of their innovative treatment.

Conclusion

With the backing of prominent investors and the strategic partnership with Cook Medical, Zenflow is poised to make significant strides in the field of BPH treatment, offering a novel solution to millions of men affected by the condition.